Amgen Inc (AMGN) Gets a Hold Rating from RBC Capital

By Austin Angelo

RBC Capital analyst Kennen MacKay maintained a Hold rating on Amgen Inc (AMGNResearch Report) yesterday and set a price target of $182. The company’s shares closed yesterday at $197.76.

According to, MacKay is a 5-star analyst with an average return of 16.0% and a 58.7% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Abeona Therapeutics, and Puma Biotechnology.

Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $207.23, implying a 4.8% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Hold rating on the stock with a $223 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $210.19 and a one-year low of $163.31. Currently, Amgen Inc has an average volume of 2.82M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.